Art. -Nr.: HY-101410

SDMA

(Synonyms: Symmetric dimethylarginine; NG,NG'-Dimethyl-L-arginine)

4 Cited Publications

Kundenbewertung

Based on 4 publication(s) in Google Scholar

SDMA (Symmetric dimethylarginine) is an endogenous inhibitor of nitric oxide (NO) synthase activity. SDMA, a novel kidney biomarker, permits earlier diagnosis of kidney disease than traditional creatinine testing.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.0%
CAS. Nr.: 30344-00-4
Formel: C₈H₁₈N₄O₂
Molecular Weight:202.25

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

SDMA Chemical Structure

CAS. Nr.: 30344-00-4

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (4)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

Human Endogenous Metabolite

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen :

Alle NO Synthase Isoform-spezifische Produkte anzeigen :

Alle NF-κB Isoform-spezifische Produkte anzeigen :

In Vitro

SDMA is the structural isomer of the cardiovascular risk marker asymmetric dimethylarginine, as an endogenous marker of renal function. SDMA does not directly inhibit NOS but is a competitor of arginine transport. SDMA is primarily eliminated by renal excretion and is a promising endogenous marker of glomerular filtration rate^[1].
SDMA inhibits dose dependently the NO synthesis in intact endothelial cells, whereas it has no effect on protein expression of NOS^[1].
SDMA is involved in the inflammatory process of chronic kidney disease, activating NF-κB and resulting in enhanced expression of IL-6 and TNF-α^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

SDMA is highly stable in serum and plasma, and the assay demonstrates excellent analytical performance. In unaffected dogs, SDMA remains unchanged whereas in affected dogs, SDMA increases during disease progression, correlating strongly with an increase in sCr and decrease in GFR^[3].
Chronic SDMA infusion leads to a significant increase of SDMA levels in mice, but the GFR did not change at 4 weeks. No histological changes are observed, particularly no effect on fibrosis or endothelias nitric oxide synthase expression. There is neither an effect of SDMA on systolic blood pressure nor on ejection fraction^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 30344-00-4
Appearance Solid
Molecular Weight 202.25
Formel C₈H₁₈N₄O₂
Color White to off-white
SMILES

N[C@@H](CCC/N=C(NC)/NC)C(O)=O
Synonyms

Symmetric dimethylarginine; NG,NG'-Dimethyl-L-arginine
Structure Classification
- Ketones, Aldehydes, Acids
Initial Source
- Endogenous metabolite
- Human Gut Microbiota Metabolites
- Microorganisms
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (4)

All

Sort by:

Journal Impact Factor

Cell Metab

Lighting up arginine metabolism reveals its functional diversity in physiology and pathology. [Abstract]

2025 Jan 7;37(1):291-304.e9. PMID: 39413790
Int J Biol Macromol

Molecular basis of BACE1 modulation revealed by machine learning, molecular simulations, and experimental validation. [Abstract]

2026 May 6:152409. PMID: 42103119
Int J Biol Macromol

Structural and dynamic characterization of papain-like protease ligand recognition using integrated computational and biochemical approaches. [Abstract]

2026 Mar 18:355:151493. PMID: 41861871
EMBO Rep

Tudor-based proteomic strategy pan-specifically enriches and identifies protein arginine methylation. [Abstract]

2025 Oct 20. PMID: 41116072

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 67.5 mg/mL (333.75 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 50 mg/mL (247.22 mM; ultrasonic and warming and heat to 60°C)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.9444 mL

24.7219 mL

49.4438 mL

5 mM

0.9889 mL

4.9444 mL

9.8888 mL

10 mM

0.4944 mL

2.4722 mL

4.9444 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (12.36 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (12.36 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: 2.5 mg/mL (12.36 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 120 mg/mL (593.33 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Protokoll

Cell Assay^[2]

SDMA stock solution is prepared in 0.9% NaCl and diluted in the cell culture medium or in heparinized whole blood resulting in a maximal uremic concentration of 6.1 μM SDMA. Whole blood is incubated with saline (control) or different doses of ADMA (0.6, 3.6, and 36 μM) or SDMA (1.5, 3.1, and 6.1 μM) for 2 hours in a humidified atmosphere of 5% CO₂ in air at 37°C. Cells are finally stained for intracellular TNF-α or IL-6. Samples are analyzed with a flow cytometer^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[4]

Mice: Eight-week-old male C57Bl/6 mice receives vehicle-controlled infusion of SDMA (250 µmol/kg/days) for 28 days using osmotic minipumps (n=24/group). Glomerular filtration rate, cardiac function and blood pressure are monitored. Blood samples for SDMA determination are obtained at baseline, 2 and 4 weeks. Mice are euthanized at 4 weeks to obtain tissue for renal histology^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Bode-Böger SM,et al. Symmetrical dimethylarginine: a new combined parameter for renal function and extent ofcoronary artery disease. [Content Brief]

[2]. Schepers E, et al. Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease.Clin J Am Soc Nephrol. 2011 Oct;6(10):2374-83. [Content Brief]

[3]. Nabity MB, et al. Symmetric Dimethylarginine Assay Validation, Stability, and Evaluation as a Marker for the EarlyDetection of Chronic Kidney Disease in Dogs. J Vet Intern Med. 2015 Jul-Aug;29(4):1036-44. [Content Brief]

[4]. Veldink H, et al. Effects of chronic SDMA infusion on glomerular filtration rate, blood pressure, myocardial function and renal histology in C57BL6/J mice. Nephrol Dial Transplant. 2013 Jun;28(6):1434-9. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	4.9444 mL	24.7219 mL	49.4438 mL	123.6094 mL
	5 mM	0.9889 mL	4.9444 mL	9.8888 mL	24.7219 mL
	10 mM	0.4944 mL	2.4722 mL	4.9444 mL	12.3609 mL
	15 mM	0.3296 mL	1.6481 mL	3.2963 mL	8.2406 mL
	20 mM	0.2472 mL	1.2361 mL	2.4722 mL	6.1805 mL
	25 mM	0.1978 mL	0.9889 mL	1.9778 mL	4.9444 mL
	30 mM	0.1648 mL	0.8241 mL	1.6481 mL	4.1203 mL
	40 mM	0.1236 mL	0.6180 mL	1.2361 mL	3.0902 mL
	50 mM	0.0989 mL	0.4944 mL	0.9889 mL	2.4722 mL
	60 mM	0.0824 mL	0.4120 mL	0.8241 mL	2.0602 mL
	80 mM	0.0618 mL	0.3090 mL	0.6180 mL	1.5451 mL
	100 mM	0.0494 mL	0.2472 mL	0.4944 mL	1.2361 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

SDMA

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Human Endogenous Metabolite Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Oxygen Sensing Compound Library

Endocrinology Compound Library

Pyroptosis Compound Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Gut Microbial Metabolite Library

Anti-Cancer Metabolism Compound Library

Microbial Metabolite Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Food-Sourced Compound Library

Anti-Cancer Natural Product Library

Human Metabolite Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Animal-Sourced Natural Product Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Endogenous Metabolite Library

Mass Spectrometry Human Metabolite Library

Natural Product Diversity Scaffold Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) SDMA

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen

Alle NO Synthase Isoform-spezifische Produkte anzeigen

Alle NF-κB Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (4)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

SDMA Related Classifications

HY-101410 Related Classifications